Cardiome Pharma Corporation (NASDAQ: CRME) and Mirna Therapeutics (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.


This table compares Cardiome Pharma Corporation and Mirna Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cardiome Pharma Corporation -110.95% -78.51% -38.30%
Mirna Therapeutics N/A -44.70% -42.29%

Valuation & Earnings

This table compares Cardiome Pharma Corporation and Mirna Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Cardiome Pharma Corporation $25.26 million 1.94 -$19.61 million ($0.83) -1.75
Mirna Therapeutics N/A N/A -$26.26 million ($6.84) -1.62

Cardiome Pharma Corporation has higher revenue and earnings than Mirna Therapeutics. Cardiome Pharma Corporation is trading at a lower price-to-earnings ratio than Mirna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

55.1% of Cardiome Pharma Corporation shares are owned by institutional investors. Comparatively, 60.9% of Mirna Therapeutics shares are owned by institutional investors. 18.6% of Mirna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Cardiome Pharma Corporation and Mirna Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiome Pharma Corporation 0 0 3 0 3.00
Mirna Therapeutics 0 2 1 0 2.33

Cardiome Pharma Corporation currently has a consensus price target of $7.58, suggesting a potential upside of 422.99%. Mirna Therapeutics has a consensus price target of $19.50, suggesting a potential upside of 75.68%. Given Cardiome Pharma Corporation’s stronger consensus rating and higher probable upside, research analysts clearly believe Cardiome Pharma Corporation is more favorable than Mirna Therapeutics.


Cardiome Pharma Corporation beats Mirna Therapeutics on 7 of the 11 factors compared between the two stocks.

Cardiome Pharma Corporation Company Profile

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Mirna Therapeutics Company Profile

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Receive News & Ratings for Cardiome Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.